Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy

被引:249
|
作者
Frangogiannis, Nikolaos G.
Dewald, Oliver
Xia, Ying
Ren, Guofeng
Haudek, Sandra
Leucker, Thorsten
Kraemer, Daniela
Taffet, George
Rollins, Barrett J.
Entman, Mark L.
机构
[1] Baylor Coll Med, Methodist Hosp, Cardiovasc Sci Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Methodist Hosp, DeBakey Heart Ctr, Houston, TX 77030 USA
[3] Univ Bonn, Dept Cardiac Surg, D-5300 Bonn, Germany
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
关键词
inflammation; ischemia; reperfusion; immunology; pathology; fibrosis; cardiomyopathy;
D O I
10.1161/CIRCULATIONAHA.106.646091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Cardiac interstitial fibrosis plays an important role in the pathogenesis of ischemic cardiomyopathy, contributing to systolic and diastolic dysfunction. We have recently developed a mouse model of fibrotic noninfarctive cardiomyopathy due to brief repetitive myocardial ischemia and reperfusion. In this model, fibrotic changes are preceded by marked and selective induction of the CC chemokine monocyte chemoattractant protein-1 (MCP-1). We hypothesized that MCP-1 may mediate fibrotic remodeling through recruitment of mononuclear cells and direct effects on fibroblasts. Methods and Results - Wild-type (WT) and MCP-1-null mice underwent daily 15-minute coronary occlusions followed by reperfusion. Additional WT animals received intraperitoneal injections of a neutralizing anti-MCP-1 antibody after the end of each ischemic episode. Hearts were examined echocardiographically and processed for histological and RNA studies. WT mice undergoing repetitive brief myocardial ischemia and reperfusion protocols exhibited macrophage infiltration after 3 to 5 days and marked interstitial fibrosis in the ischemic area after 7 days, accompanied by ventricular dysfunction. MCP-1-null mice had markedly diminished interstitial fibrosis, lower macrophage infiltration, and attenuated ventricular dysfunction compared with WT animals. MCP-1 neutralization also inhibited interstitial fibrosis, decreasing left ventricular dysfunction and regional hypocontractility. Cardiac myofibroblasts isolated from WT but not from MCP-1-null animals undergoing repetitive myocardial ischemia and reperfusion demonstrated enhanced proliferative capacity. However, MCP-1 stimulation did not induce cardiac myofibroblast proliferation and did not alter expression of fibrosis-associated genes. Conclusions - Defective MCP-1 signaling inhibits the development of ischemic fibrotic cardiomyopathy in mice. The profibrotic actions of MCP-1 are associated with decreased macrophage recruitment and may not involve direct effects on cardiac fibroblasts.
引用
收藏
页码:584 / 592
页数:9
相关论文
共 50 条
  • [1] Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia
    Blomqvist, HM
    Olsson, AG
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2003, 63 (7-8) : 513 - 519
  • [2] Inhibitors of monocyte chemoattractant protein-1/CC ligand 2 and its receptor CCR2
    Howard, OMZ
    Yoshimura, T
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (07) : 1147 - 1151
  • [3] Monocyte chemoattractant protein-1 /CC chemokine ligand 2 enhances apoptotic cell removal by macrophages through Rac1 activation
    Tanaka, Takeshi
    Terada, Mayumi
    Ariyoshi, Koya
    Morimoto, Konosuke
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 399 (04) : 677 - 682
  • [4] Expression of monocyte chemoattractant protein-1 in idiopathic dilated cardiomyopathy
    Kobayashi, Makoto
    Nakamura, Kazufumi
    Kusano, Kengo Fukushima
    Nakamura, Yoichi
    Ohta-Ogo, Keiko
    Nagase, Satoshi
    Sakuragi, Satoru
    Ohe, Tohru
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 126 (03) : 427 - 429
  • [5] Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 α in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy
    Göser, S
    Öttl, R
    Brodner, A
    Dengler, TJ
    Torzewski, J
    Egashira, K
    Rose, NR
    Katus, HA
    Kaya, Z
    CIRCULATION, 2005, 112 (22) : 3400 - 3407
  • [6] Correlation between monocyte chemoattractant protein-1/chemokine (C-C motif) ligand 2 and coronary plaque characteristics
    Li, Meng
    Chen, Yan
    Zhang, Yan
    Li, Danna
    Liu, Jun
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 245 (15) : 1335 - 1343
  • [7] Monocyte chemoattractant protein-1 and the kidney
    Haller, Hermann
    Bertram, Anna
    Nadrowitz, Felix
    Menne, Jan
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2016, 25 (01) : 42 - 49
  • [8] Association of Monocyte Chemotactic Protein-1 and CC Chemokine Receptor 2 Gene Variants with Preeclampsia
    Agachan, Bedia
    Attar, Rukset
    Isbilen, Elif
    Aydogan, Hulya Yilmaz
    Sozen, Seyma
    Gurdol, Figen
    Isbir, Turgay
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2010, 30 (09) : 673 - 676
  • [9] Investigation of the functional role played by the chemokine monocyte chemoattractant protein-1 in interleukin-1-induced murine peritonitis
    Ajuebor, MN
    Gibbs, L
    Flower, RJ
    Das, AM
    Perretti, M
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (02) : 319 - 326
  • [10] Monocyte chemoattractant protein-1 and hypertension: An overview
    Cortez, A.
    Muxfeldt, E.
    HIPERTENSION Y RIESGO VASCULAR, 2022, 39 (01): : 14 - 23